Compare Moderna, Inc. (MRNA) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oscar Health Inc — how do they compare? Moderna, Inc. trades at $221.45 (market cap $78.65B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Moderna, Inc. is far larger — about 7.7× Oscar Health Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Oscar Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Oscar Health Inc for 15 Days on average.
| MRNA | OSCR | |
|---|---|---|
Market Cap | $78.65B | $10.22B |
Volume | 37,373,437 | 4,123,394 |
Sector | Health | Health |
52-Week High | $203.46 | $33.81 |
52-Week Low | $22.36 | $10.85 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $74.80B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
